Clinical Trial Detail

NCT ID NCT03874052
Title Ruxolitinib in Combination With Venetoclax for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

acute myeloid leukemia

Therapies

Ruxolitinib + Venetoclax

Age Groups: senior adult

No variant requirements are available.